PLYX

Polaryx Therapeutics, Inc. Common Stock

There isn't enough reported data to score PLYX yet.

PLYX Fundamentals

MetricStatus
Unavailable
Weak
Unavailable
Unavailable

PLYX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.

PLYX PE Valuation

PLYX has no meaningful PE right now: it lost money over the past year.

PLYX Forward outlook

MetricOutlook
--
Losses growing
--
--
Limited
Moderate

Analysts expect PLYX's losses to grow, with revenue holding steady.

PLYX Risk to reward

ScenarioChangePrice
UpsideUnknown—
DownsideUnknown—

Calculated from the latest close: $1.88 on Nov 12.

There is not enough scenario data to assess PLYX's risk to reward.

PLYX Earnings Per Share

Q2 2025: $-0.04Q3 2025: $-0.04Q4 2025: $-0.07Q1 2026: $-0.09Q2 2026: $-0.12Q3 2026: $-0.18
Q2 2025: $-0.04Q3 2025: $-0.04Q4 2025: $-0.07Q1 2026: $-0.09Q2 2026: $-0.12Q3 2026: $-0.18
QuarterTTM EPSYoY
Q3 2026-$0.18-$0.14
Q2 2026-$0.12-$0.08

PLYX lost $0.18 per share over the past year, and its loss has widened in each of the last four quarters.

PLYX Quarterly Revenue

Q1 2024: --Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: --Q2 2026: --Q3 2026: --
Q1 2024: --Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: --Q2 2026: --Q3 2026: --

PLYX Free Cash Flow

Q1 2024: --Q3 2024: −$1MQ4 2024: −$860,000Q1 2025: −$709,000Q2 2025: −$858,000Q3 2025: −$887,000Q4 2025: −$1MQ1 2026: −$2MQ2 2026: −$1MQ3 2026: −$3M
Q1 2024: --Q3 2024: −$1MQ4 2024: −$860,000Q1 2025: −$709,000Q2 2025: −$858,000Q3 2025: −$887,000Q4 2025: −$1MQ1 2026: −$2MQ2 2026: −$1MQ3 2026: −$3M
QuarterFree cash flowYoY
Q3 2026-$3.1M-$2.2M
Q2 2026-$1.4M-$511K
Q1 2026-$2.1M-$1.4M
Q4 2025-$1.5M-$630K
Q3 2025-$887K+$445K

PLYX has burned cash in almost every quarter: −$8M over the past year, against −$3M the year before.

PLYX Total Shares

Q3 2024: 189MQ4 2024: 189MQ1 2025: 189MQ2 2025: 189MQ3 2025: 189MQ4 2025: 47MQ1 2026: 47MQ2 2026: 48MQ3 2026: 50M
Q3 2024: 189MQ4 2024: 189MQ1 2025: 189MQ2 2025: 189MQ3 2025: 189MQ4 2025: 47MQ1 2026: 47MQ2 2026: 48MQ3 2026: 50M
PeriodChange %Net change
Quarterly+3.2%+1.6M shares
1 year-74%-140M shares

PLYX has 50M diluted shares, down 74% from a year ago.

PLYX Net Leverage

PLYX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.

PLYX Weekly Momentum

MetricValueStatus
RSI15.3Oversold
Stochastic10.1Oversold

PLYX's weekly RSI is 15 (oversold) and its Stochastic is 10 (oversold).

PLYX PE vs Healthcare Sector

PLYX has no meaningful PE right now: it lost money over the past year.

PLYX Weekly Moving Averages

Moving averageMA priceRelative
8 week MA$1.922.1% below
20 week MA$2.1111% below

PLYX is in a downtrend: it's below all two of its weekly moving averages, and 11% below its 20-week average.

PLYX Yearly ROI

YearStart priceEnd priceROI
2026 YTD$8.91$1.88-79%

It's down 79% so far in 2026.

Give your agent the market.

Get API key